Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Neuroprotective drugs in the treatment of ocular ischemic syndrome

Poster Details

First Author: D. Makhkamova UZBEKISTAN

Co Author(s):    M. Kasimova                    

Abstract Details


To study the efficacy of neuroprotective drugs in patients with ocular ischemic syndrome


Tashkent institute of Postgraduate Medical Education


We examined 73 patients with a diagnosis of OIS. Of these 49 men and 24 women, aged 58 to 73 years. Patients depending on the therapy were divided into 2 groups. In the main group 31 patients used etiotropic, antiischemic and nootropic treatment. In the control group of 33 patients received etiotropic and anti-ischemic treatment. As a nootropic drug therapy used Nootcin (piracetam 400 mg + 25 mg cinnarizine), which is a combination drug with antihypoxic, neuroprotective and vasodilating effects. Patients of the main group the drug was administered 1 capsule 3 times daily for 3 months.


In the main group visual acuity of patients after treatment in the affected eye improved by 25.9%, IOP within the normal range. In the control group visual acuity in the affected eye improved by 7.3%, IOP within the normal range. After treatment in the main group showed an increase in the speed parameters of the ophthalmic artery by 44.9%. After treatment in the control group in 21 patients showed an increase in the speed parameters of the ophthalmic artery by 10.7%.


The use of neuroprotective therapy in ocular ischemic syndrome, including nootropic treatment has a positive effect on the course of the disease - improves visual acuity, expanding the total boundaries of the visual field, reduced sectoral loss in field of vision, the positive dynamics of OCT parameters, improve speed performance on Doppler of eye in dynamics.

Financial Disclosure:


Back to Poster listing